Envoy Medical Selects Study Sites for Trial of Fully Implanted Cochlear Implant
Envoy Medical has chosen seven investigational sites for its pivotal clinical trial of the fully implanted Acclaim cochlear implant.
Envoy Medical has chosen seven investigational sites for its pivotal clinical trial of the fully implanted Acclaim cochlear implant.
The Phase I part of the study confirmed the safety and tolerability of a dose of 250 microgram of Gamma Secretase Inhibitor LY3056480.
Nuheara has engaged National Acoustics Laboratories (NAL) under the terms of a Clinical Trial Agreement (CTA) to assist with conducting clinical trials for obtaining FDA and CE compliance for its hearing devices.
AK-OTOF is intended to treat individuals with sensorineural hearing loss due to mutations in the OTOF gene, who typically have severe hearing loss in both ears from birth, by promoting the expression of normal, functional otoferlin protein in affected cells of the cochlea.
Read MoreSENS-401 is under development in the treatment of Sudden Sensorineural Hearing Loss (or SSNHL).
Read MoreSENS-401 is under development in the treatment of Sudden Sensorineural Hearing Loss (or SSNHL).
Read MoreSENS-401 is under development in the treatment of Sudden Sensorineural Hearing Loss (or SSNHL).
Read MoreThe randomized, double-blind, placebo-controlled Phase 1/2 study will include an initial safety cohort followed by an exploratory efficacy study that will enroll approximately 50 patients with subjective tinnitus.
Read MoreLY3056480 mediated Notch inhibition is aimed at regeneration of inner ear sensory hair cells that are lost with advancing age.
Read MoreThese preclinical data, demonstrating the potential of intratympanic BDNF to repair cochlear synaptopathy—an underlying cause of hearing loss including speech-in-noise hearing difficulty—are being presented as part of the Society for Neuroscience (SfN) Annual Meeting in San Diego, November 3-7, 2018.
Read MoreHearing Review interviewed Rick Friedman, MD, PhD, about NF2 and an NF2 clinical that is underway in Los Angeles and at 12 other sites in the US. The trial uses the chemotherapy drug Avastin (bevacizumab) as a potential therapy for shrinking NF2 tumors, or stemming their growth.
Read MoreOtonomy, which develops and commercializes therapeutics for ear diseases and disorders, reported that its development of investigational drugs to help patients with Ménière’s disease and tinnitus, have had positive results in clinical trials.
Read MoreAuris Medical announced it has initiated patient enrollment in the ASSENT Phase 3 clinical trial of AM-111, a drug for treating idiopathic sudden sensorineural hearing loss, or sudden deafness. The drug must be administered within 72 hours after onset of hearing loss.
Read MoreThe University of Southampton Auditory Implant Service has launched a new clinical trial involving 60 patients, half of whom will use an online care package to determine whether the routine annual clinic check-up of hearing and device status can be replaced with a personalized online version.
Read MoreAuris Medical Holding AG, a Swiss biopharmaceutical company, announced enrollment of the first patient into the HEALOS clinical trial to test the drug, AM-111, as a therapy for sudden hearing loss. The trial involves 255 patients suffering from acute severe to profound hearing loss within 72 hours from onset.
Read MoreMore than half the participants who completed TMS sessions on 10 consecutive workdays found their tinnitus symptoms were alleviated for at least six months.
Read MoreAuris Medical Holding and Cochlear Limited announced they will collaborate on a planned randomized placebo-controlled clinical trial in the US (the REACH trial) to investigate otoprotection during cochlear implant (CI) surgery.
Read MoreAuris Medical, a Switzerland-based clinical-stage company developing therapeutics for hearing conditions, announced publications in two peer-reviewed journals related to AM-101, the company’s drug developed for treating acute inner ear tinnitus.
Read More